Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rivastigmine for Antimuscarinic Delirium: a Randomized, Placebo-controlled Trial

NCT06382649 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT06382649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06382649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rivastigmine for Antimuscarinic Delirium: a Randomized, Placebo-controlled Trial
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Recruiting
Start date
June 30, 2026
Completion date
December 31, 2028
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anticholinergic toxicity